Bioxytran, Inc. has reported its financial results for the fiscal year ending December 31, 2025, revealing a net loss of $2.1 million, a decrease from the $2.4 million loss recorded in the previous year. The company's total revenue remains at zero, as it continues to focus on research and development activities without generating sales. The accumulated deficit has increased to approximately $21 million, up from $18.9 million in 2024. The company’s cash position improved significantly, ending the year with $509,914 compared to just $5,154 at the end of 2024, primarily due to successful fundraising efforts.
In terms of operational developments, Bioxytran has made strides in its clinical trials, particularly with its lead drug candidate, ProLectin-M, which is aimed at treating COVID-19. The company has received approval for a Phase 3 trial, expected to commence in the third quarter of 2026, contingent on securing adequate funding. Additionally, Bioxytran has been actively pursuing partnerships and collaborations to enhance its research capabilities and market reach, including the acquisition of NDPD Pharma, Inc., which has expanded its portfolio of drug candidates.
The company’s research and development expenses surged to $454,000 in 2025, compared to $112,337 in 2024, reflecting increased investment in clinical trials and product development. General and administrative expenses also decreased to $1.39 million from $2.11 million, largely due to reduced marketing activities and salary adjustments among executives. The company’s workforce remains small, with only two full-time employees, which has implications for its operational capacity and financial management.
Looking ahead, Bioxytran anticipates needing to raise approximately $3.7 million to sustain operations and continue its development activities over the next 15 months. The company is exploring various financing options, including private placements and public offerings, but acknowledges the uncertainty surrounding its ability to secure these funds. The management has expressed concerns about the company's ability to continue as a going concern if it fails to obtain the necessary capital.
As of April 15, 2026, Bioxytran's market capitalization was approximately $9.3 million, based on a share price of $0.1048. The company has 113,361,886 shares of common stock outstanding, with a significant portion held by its executive team and affiliates. The ongoing development of its drug candidates, particularly in the fields of glycovirology and hypoxia, remains a critical focus as the company seeks to address unmet medical needs in these areas.
About BIOXYTRAN, INC
Bioxytran, Inc. is a clinical-stage pharmaceutical company developing therapeutic drugs targeting hypoxia, a condition of oxygen deficiency in tissues. Its lead candidate, BXT-25, is a novel oxygen-carrying small molecule designed to treat stroke-related brain hypoxia. Through its subsidiary Pharmalectin, the company develops galectin antagonist-based therapies for viral diseases, including COVID-19. Bioxytran focuses on innovative co-polymer chemistry, leveraging proprietary technology to address unmet medical needs via licensing partnerships.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.